Login
Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

Watchlist

Keep track of companies that you follow and research.

10 Years of Data

Full access to our data with predictions and indicators that we calculate daily.

Screener

Full access to our screener with tons of custom values and customizable email notifications.

XLS Exports

Excel export of financials and screeners you define and save.

BioCryst Pharmaceuticals, Inc. BCRX

Healthcare — Drug Manufacturers Specialty & Generic
Cash Flow Champion (3y)
Growth Flags show if company had growth for consecutive years

We limit data available in the Overview Report for users who do not have Powerpack

Get access to target analyst prices, predictions, compound annual growth rates and more than four years of historical data.
Register an account and get your Powerpack now or Login

Insider Decisions

Total sells
4.14
in millions of $
Nov 25 Feb 26 May 26 Aug 26
Buy — — — — — — — — — — — —
Sell — 1 3 — — 2 — 2 — — — —
Insider Ownership
13.68%

Capital & Financial Ratios

Market Cap
2,200.00
Revenue
940.61
Net Income
(384.67)
Free Cash Flow
373.93
Net Debt
486.35
Current Ratio
2.32
Debt/Equity
(1.85)
P/E ratio
0.00
P/S ratio
2.35
P/B ratio
0.00
Past 5Y EPS Growth
14.52%
This Y EPS Growth
(290.94%)
Next Y EPS Growth
125.05%
Next 5Y EPS Growth
(16.36%)
in millions of $

Dividends

Payout Ratio
0.00
Annual Dividend Rate
—
Annual Dividend Yield
3.71%
total individual payouts
2025 ‡‡‡
2024 ‡‡‡
2023 ‡‡‡
2022 ‡‡‡
2021 ‡‡‡
2020 ‡‡‡
2019 ‡‡‡
2017 ‡‡‡
predictions in italic, special payouts not included in total or ratios

Assets vs Liabilities

2023 2024 2025 Q'26
Cash 390.79 321.06 274.95 353.05
Receivables 56.95 79.07 106.82 110.76
Inventory 28.68 8.09 5.40 6.06
Other — — — —
495.97 421.97 404.35 484.68
2023 2024 2025 Q'26
Payables 20.89 11.64 15.83 11.46
ST’ Debt 23.57 32.68 52.20 60.17
Other — — — —
149.99 160.38 196.07 208.85
in millions of $

Compound Annual Growth

10y 5y 3y
Sales ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Cash Flow ‡‡‡ ‡‡‡ ‡‡‡
Earnings ‡‡‡ ‡‡‡ ‡‡‡
Book Value ‡‡‡ ‡‡‡ ‡‡‡

Revenue

Mar Jun Sep Dec Year
’26 156.41 218.25 — —
—
’25 145.53 163.35 159.40 406.56
874.84
’24 92.76 109.33 117.09 131.53
450.71
’23 68.78 82.49 86.74 93.40
331.41
’22 49.92 65.53 75.83 79.55
270.83
’21 19.06 49.96 40.99 47.16
157.17
’20 4.82 2.87 6.10 4.02
17.81
in millions of $

Operating Cash Flow

Mar Jun Sep Dec Year
’26 (61.79) 104.34 — —
—
’25 (27.52) 41.30 41.62 291.96
347.37
’24 (53.68) (1.37) 8.25 (5.21)
(52.02)
’23 (47.51) (18.81) (19.90) (8.92)
(95.14)
’22 (77.80) (27.76) (32.44) (23.85)
(161.85)
’21 (61.01) (25.41) (23.28) (32.46)
(142.16)
’20 (23.28) (31.04) (38.25) (42.53)
(135.11)
in millions of $

Free Cash Flow

Mar Jun Sep Dec Year
’26 (62.19) 104.13 — —
—
’25 (27.66) 41.12 40.28 291.71
345.45
’24 (53.92) (1.52) 8.19 (5.89)
(53.14)
’23 (47.67) (19.28) (20.88) (9.47)
(97.31)
’22 (78.21) (28.00) (32.62) (24.37)
(163.20)
’21 (61.11) (26.22) (23.64) (33.57)
(144.54)
’20 (23.40) (31.11) (38.43) (42.69)
(135.62)
in millions of $

EPS

Mar Jun Sep Dec Year
’26 (2.98) 0.30 — —
—
’25 0.00 0.02 0.06 1.12
1.21
’24 (0.17) (0.06) (0.07) (0.13)
(0.43)
’23 (0.28) (0.40) (0.19) (0.31)
(1.18)
’22 (0.40) (0.32) (0.23) (0.38)
(1.33)
’21 (0.36) (0.24) (0.33) (0.10)
(1.03)
’20 (0.24) (0.24) (0.26) (0.34)
(1.09)

Target Price Range

High
‡‡‡‡‡
‡‡‡‡
Average
‡‡‡‡‡
‡‡‡‡
Low
‡‡‡‡‡
‡‡‡‡

Recommendation Rating

1.4
1
Buy
2
3
Hold
4
5
Sell
2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028
‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ 7.61 4.83 4.03 6.00 — — —
Low Price
‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ 19.99 12.08 8.88 11.31 — — —
High Price
‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 531 536 580 435 — — —
Employees
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 0.51 0.62 0.78 2.01 — — —
Revenue/Emp
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 270.83 331.41 450.71 874.84 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 97.63% 98.65% 97.28% 97.82% — — —
Gross Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (244.38) (226.23) (86.95) 267.39 — — —
EBT
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (90.24%) (68.26%) (19.29%) 30.56% ‡‡‡ ‡‡‡ ‡‡‡
EBT Margin
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (247.12) (226.54) (88.88) 263.86 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.34) (8.61) (10.23) (2.94) — — —
Depreciation
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 1.46 1.72 2.18 4.17 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Revenue/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.33) (1.18) (0.43) 1.26 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Earnings/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.87) (0.49) (0.25) 1.66 ‡‡‡‡‡ — —
Cash Flow/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.01) (0.01) (0.01) (0.01) ‡‡‡ ‡‡‡ ‡‡‡
Capex/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (0.88) (0.51) (0.26) 1.65 — — —
Free CF/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.58) (2.37) (2.30) (0.57) ‡‡‡‡‡ — —
Book Value/Sh
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 185.91 192.20 206.70 209.89 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 6.24 ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡
PE Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 7.86 3.52 3.45 1.87 ‡‡‡ ‡‡‡ ‡‡‡
PS Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ 0.00 0.00 0.00 0.00 ‡‡‡ ‡‡‡ ‡‡‡
PB Ratio
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 9.01 4.87 4.58 2.11 ‡‡‡‡ ‡‡‡‡ ‡‡‡‡
EV/Sales
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (14.95) (16.58) (38.84) 5.34 — — —
EV/FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (161.85) (95.14) (52.02) 347.37 ‡‡‡ ‡‡‡ ‡‡‡
Op' Cash Flow
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (1.35) (2.17) (1.12) (1.92) ‡‡‡‡‡ ‡‡‡‡‡ —
Capex
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (163.20) (97.31) (53.14) 345.45 ‡‡‡‡‡ — —
FCF
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 410.99 345.98 261.58 208.28 — — —
Working Cap'
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 737.43 837.68 830.72 480.87 — — —
Total Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 311.64 446.88 509.66 205.92 — — —
Net Debt
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (294.60) (455.53) (475.93) (119.15) — — —
Sh' Equity
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ (43.42%) (42.46%) (17.65%) 52.53% — — —
ROA
‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡ (544.24%) 0.00% (4.71%) 245.61% — — —
ROIC
‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ 123.07% 60.40% 19.08% (88.68%) — — —
ROE
predictions in italic, sparklines do not include predictions

Analyst Commentary (Summary)

BioCryst Pharmaceuticals (BCRX) has transformed from chronic losses to revenue powerhouse with ORLADEYO, its FDA-approved HAE prophylaxis drug launched in 2020, driving sales from $17.8 million to $450.7 million in 2024—a staggering 120%+ CAGR. Gross margins exceed 95%, revenue per employee doubled to $777,000, and analysts forecast 37% growth to $619.6 million in 2025, extending to $729 million by 2027. Yet, despite this momentum, shares trade near 2024 lows after a post-2022 plunge, pressured by biotech volatility, with price targets signaling 92-373% upside from current levels.

Profitability beckons: EPS improves from -$0.43 in 2024 to +$0.48 by 2027, with operating cash flow turning positive and FCF projected at $47 million in 2025. Balance sheet strains persist, however, with debt ballooning to $830 million and shares diluted to 207 million, yielding a cheap 3.4x 2024 PS ratio versus historical 40x+ peaks and forward EV/Sales dropping to 2.3x by 2027.

Insider sells without buys add caution amid HAE competition and refinancing risks, but ORLADEYO’s market share gains, pipeline potential, and FCF inflection could propel re-rating to 2022 highs—offering asymmetric rewards for execution-focused investors.

Read full commentary →

BioCryst Pharmaceuticals, Inc. (BCRX) Latest News

News by impact score

Fine-tune

18 Sep

4 www.marketbeat.com, 10:01 PM
BioCryst Pharmaceuticals targets $1 billion rare-disease revenue via external innovation to expand its pipeline and market position. External innovation strategy targets $1B rare-disease expansion and alters long-term company trajectory.

17 Sep

4 , 12:06 PM
BioCryst Pharmaceuticals reports its first profit and plans acquisitions of rare disease drugs to expand its portfolio. First profit and acquisition strategy signal major growth move with significant effects on financial trajectory and investor outlook.

14 Sep

3 , 12:10 PM
BioCryst Pharmaceuticals (BCRX) could be 62% undervalued based on the growth prospects of its ORLADEYO treatment. Valuation upside tied to ORLADEYO growth has potential to influence BCRX stock performance moderately.

10 Sep

3 stocktwits.com, 11:52 AM
BCRX stock falls for fifth consecutive day as RBC Capital cites challenging near-term outlook for BioCryst Pharmaceuticals. RBC Capital negative near-term outlook directly pressures BCRX stock performance and short-term investor sentiment.

3 , 11:42 AM
RBC reports BioCryst Pharmaceuticals faces competitive pressure in hereditary angioedema treatment. Competitive pressure in hereditary angioedema treatment may moderately influence BioCryst's market position and performance.

8 Sep

4 stocktwits.com, 7:24 PM
BCRX shares dropped sharply for their worst day in over six months after PHVS reported a successful trial win in rare swelling disease, indicating stronger competitive pressure in the space. PHVS trial success directly intensifies competition against BCRX in the rare disease market and pressures its trajectory.

3 , 4:45 PM
BioCryst selects CareMed as national pharmacy partner for Orladeyo (berotralstat). CareMed adds Orladeyo to its rare disease portfolio. Expanded pharmacy partnership may boost Orladeyo accessibility and support modest revenue growth.

28 Aug

4 stocktwits.com, 7:40 PM
Orladeyo sales have built BioCryst cash reserves, prompting CEO Gayer to target acquisition of the next asset for portfolio expansion. Orladeyo cash enables acquisition strategy that can expand BioCryst portfolio and shift long-term growth trajectory.

25 Aug

4 , 7:01 AM
BioCryst Pharmaceuticals secures Japanese approval for ORLADEYO to treat hereditary angioedema in pediatric patients. Pediatric approval expands ORLADEYO access in Japan and increases potential revenue from a new patient segment.

13 Aug

3 , 5:10 AM
BioCryst Pharmaceuticals (BCRX) shares rose after the company released its latest update. Positive update prompted immediate share price increase with moderate effects on near-term market sentiment.

12 Aug

3 transcript www.fool.com, 1:29 PM
BioCryst (BCRX) released its Q2 2026 earnings call transcript covering quarterly financial results, operational updates and forward outlook. Earnings call delivers financial metrics and guidance that can moderately shift near-term investor sentiment and valuation.

11 Aug

4 247wallst.com, 9:20 AM
BioCryst Pharmaceuticals is positioned as a profitable rare-disease company that could attract acquirers, with speculation on potential buyers likely to influence its valuation and market performance. Speculation on acquisition targets signals major strategic interest capable of altering BioCryst's trajectory and investor sentiment.

5 Aug

4 transcript , 5:05 PM
BioCryst Pharmaceuticals Inc reported record revenue during its Q2 2026 earnings call. Record revenue directly strengthens financial outlook and investor sentiment for BCRX.

4 stocktwits.com, 10:39 AM
BioCryst Pharmaceuticals advances rare genetic disorder therapy expansion after Q2 earnings beat, triggering retail buyout speculation. Therapy expansion after earnings beat plus buyout speculation signals major trajectory and sentiment shifts for BCRX.

3 transcript app.moby.co, 12:50 PM
BioCryst Pharmaceuticals, Inc. held its Q2 2026 earnings call covering quarterly financial results, operational updates, and forward guidance. Quarterly earnings calls typically provide financial metrics and outlook that moderately influence near-term stock sentiment and valuation.

3 www.marketbeat.com, 10:04 AM
BioCryst Pharmaceuticals reported Q2 financial results and operational updates during its earnings call, including revenue figures, pipeline progress, and forward-looking guidance. Q2 earnings highlights and guidance provide moderate insight into financial performance and outlook.

3 , 9:00 AM
BioCryst Pharmaceuticals exceeded Q2 earnings and revenue estimates. Quarterly earnings and revenue beats can lift near-term stock performance and sentiment but rarely shift long-term company trajectory.

3 , 7:00 AM
BioCryst Pharmaceuticals reported its second quarter 2026 financial results. Quarterly financial results provide key performance data that can shift investor views on the company.

15 Jul

3 , 7:00 AM
BioCryst Pharmaceuticals appoints David W. Jenkins as Chief Scientific Officer. CSO hire can steer R&D priorities and pipeline progress.

8 Jul

4 , 10:11 PM
BioCryst Pharmaceuticals ends internal discovery programs and closes Birmingham facility. Ending internal discovery and closing facility reduces R&D capacity and operational footprint substantially.

29 Jun

4 , 8:06 AM
BioCryst Pharmaceuticals will discontinue internal discovery programs and close its Birmingham facility by year-end. Discontinuing discovery programs and closing facility signals major operational restructuring with significant effects on future innovation and costs.

4 , 7:00 AM
BioCryst Pharmaceuticals is winding down internal discovery programs and closing its Birmingham research facility to sharpen focus on external innovation. Winding down internal discovery and closing the Birmingham facility constitutes a major strategic restructuring of R&D operations with potential to alter long-term trajectory.

12 Jun

3 , 7:00 AM
BioCryst presented new clinical data and real-world evidence on its HAE portfolio at the 2026 European Academy of Allergy and Clinical Immunology Annual Meeting. Conference data presentations on BioCryst's HAE drugs moderately influence market sentiment and product positioning without immediate financial or regulatory shifts.

6 Jun

3 www.marketbeat.com, 3:12 AM
BioCryst Pharmaceuticals reaffirms its positive outlook for ORLADEYO while advancing the Navenibart trial. ORLADEYO outlook support combined with Navenibart trial progress points to moderate influence on BioCryst pipeline and positioning.

12 May

4 Simply Wall St., 12:18 PM
BioCryst Pharmaceuticals (BCRX) shares dropped 6.7% after a Q1 loss and Navenibart deal announcement, raising questions about the bull case's viability. Q1 loss and Navenibart deal triggered 6.7% stock decline, signaling potential shifts in financial trajectory and strategic outlook.

4 Simply Wall St., 3:10 AM
BioCryst Pharmaceuticals (BCRX) valuation analyzed after Q1 results showed revenue growth and amid Navenibart licensing deal with a major pharma partner, highlighting pipeline expansion and future growth potential. Q1 results and Navenibart licensing deal introduce major strategic pipeline expansion with high revenue potential for BCRX.

6 May

4 transcript www.fool.com, 3:11 PM
BioCryst Pharmaceuticals (BCRX) Q1 2026 earnings call transcript released, detailing quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses financial performance and strategic outlook, poised to significantly sway BCRX stock trajectory and investor confidence.

4 app.moby.co, 12:48 PM
BioCryst Pharmaceuticals, Inc. (BCRX) released Q1 2026 earnings call summary detailing financial results, revenue growth, operational updates, pipeline progress, and forward guidance. Q1 earnings call summary reveals financial performance, strategic initiatives, and guidance that significantly shape BCRX's market trajectory and investor confidence.

3 www.marketbeat.com, 10:55 AM
BioCryst Pharmaceuticals Q1 earnings call highlighted revenue growth from ORLADEYO, positive clinical progress on BCX10013 and other pipeline candidates, cost management efforts, and reaffirmed 2024 guidance amid strong demand. Quarterly earnings highlights affect financial performance and investor sentiment but are balanced by ongoing pipeline risks.

3 Zacks, 9:30 AM
BioCryst Pharmaceuticals (BCRX) reported a Q1 net loss but beat revenue estimates. Q1 loss with revenue beat affects financial performance and market sentiment moderately.
© 2016–2026 stockrow.com Terms and Conditions Indicators Weekly Summary Contact Us